A Multicenter, Randomized, Open-Label Study to Compare the Effects of Gemigliptin Add-on or Escalation of Metformin Dose on Glycemic Control and Safety in Patients with Inadequately Controlled Type 2 Diabetes Mellitus Treated with Metformin and SGLT-2 Inhibitors (SO GOOD Study)

Figure 2

(a) Changes in HbA1c level from baseline to week 24. When HbA1c repeatedly measured from baseline to 24 weeks were analyzed using a mixed model for repeated data, significant differences were observed between the groups ( for ). There was a significant difference between the two groups at 12 weeks and 24 weeks through the Bonferroni post hoc correction. Error bars indicate 95% confidence intervals. (b) Proportion of participants achieving and at weeks 12 and 24.

(a)

(b)